Our heritage
Built on a legacy of innovation, we aim to make more progress advancing health for humanity in the next decade than we have in the last century. As part of Johnson & Johnson, we work to understand and address the serious health problems of today and unlock the potential medicines of tomorrow.
In 2010, the pharmaceutical companies of Johnson & Johnson adopted a common identity—the Janssen Pharmaceutical Companies of Johnson & Johnson. Coming together as “One Team” strengthened our connection as a global organization. The Janssen name comes from Dr. Paul Janssen, who founded Janssen Pharmaceutica N.V. in 1953. The name embodies our commitment to finding solutions for patients by advancing science and medicine.
Dr. Paul, as he was known throughout the global scientific community, was an exceptionally gifted and passionate scientist who revolutionized modern medicine and inspired a new generation of researchers. His life was dedicated to creating medicines that met the unmet needs of millions of patients. Janssen Pharmaceutica N.V. was acquired by Johnson & Johnson in 1961. That, and earlier acquisitions of McNeil Pharmaceutical and Cilag Chemie in 1959, became the foundation of our pharmaceutical business today.
In September 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson became Johnson & Johnson Innovative Medicine. Our new brand truly reflects the best of who we are and what we do.
Patients inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science and compassion, we confidently address some of the most complex diseases of our time and unlock the potential medicines of tomorrow.
Our diverse portfolio spans multiple therapeutic areas — Oncology, Immunology, Neuroscience, Cardiopulmonary, and Specialty Ophthalmology.
We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way.
Explore our website to find out more about how we’re leading where medicine is going.
Dr. Paul, as he was known throughout the global scientific community, was an exceptionally gifted and passionate scientist who revolutionized modern medicine and inspired a new generation of researchers. His life was dedicated to creating medicines that met the unmet needs of millions of patients. Janssen Pharmaceutica N.V. was acquired by Johnson & Johnson in 1961. That, and earlier acquisitions of McNeil Pharmaceutical and Cilag Chemie in 1959, became the foundation of our pharmaceutical business today.
In September 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson became Johnson & Johnson Innovative Medicine. Our new brand truly reflects the best of who we are and what we do.
Patients inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science and compassion, we confidently address some of the most complex diseases of our time and unlock the potential medicines of tomorrow.
Our diverse portfolio spans multiple therapeutic areas — Oncology, Immunology, Neuroscience, Cardiopulmonary, and Specialty Ophthalmology.
We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way.
Explore our website to find out more about how we’re leading where medicine is going.
When Janssen Pharmaceutica N.V. was acquired by Johnson & Johnson in the early 1960s, a fruitful collaboration that continues to this day was born. Learn about the man who filed over 100 patents and developed dozens of life-changing medications.
New identity. Same purpose.
Formerly known as Janssen, The Pharmaceutical Companies of Johnson & Johnson), Johnson & Johnson Innovative Medicine innovates with purpose to lead where medicine is going.
Inspired by patients and the legacy of industry pioneer Dr. Paul Janssen, we continue with the vision of developing science-based innovations to change and save lives. Today, we pursue new pathways, collaborate closely with doctors and analyze data to deliver safe, reliable and effective products that will transform the future of health.
Inspired by patients and the legacy of industry pioneer Dr. Paul Janssen, we continue with the vision of developing science-based innovations to change and save lives. Today, we pursue new pathways, collaborate closely with doctors and analyze data to deliver safe, reliable and effective products that will transform the future of health.